Stenkrona, Per https://orcid.org/0000-0002-5529-3336
Matheson, Granville J.
Cervenka, Simon
Sigray, Pontus Plavén
Halldin, Christer
Farde, Lars
Funding for this research was provided by:
Vetenskapsrådet (2015-02398)
Pfizer
Article History
Received: 12 April 2018
Accepted: 27 June 2018
First Online: 2 August 2018
Ethics approval and consent to participate
: The study was conducted in compliance with the ethical principles originating in the Declaration of Helsinki and the Good Clinical Practice (GCP) Guidelines of the International Conference on Harmonization (ICH). The study was approved by the Regional Ethical Review Board in Stockholm, Sweden (registration number 2013/1703-31/1) and the Radiation Safety Committee at the Karolinska University Hospital in Solna, Stockholm, Sweden (registration number K1865-2013). Written informed consent to participate was obtained from all individual participants.
: Not applicable.
: LF is a shareholder of AstraZeneca. All other authors declare that they have no competing interest.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.